Beam Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $156M+145.7% YoYTTM through 30 Jun 2026
Net Income -$86.5MTTM through 30 Jun 2026
Free Cash Flow -$372.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -228.0% |
| Operating Margin | -274.6% |
| Net Margin | -55.5% |
Returns
-6.5%ROE
-5.4%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.02x
Net Debt-$1.2Bnet cash position
Cash & Equivalents$219.8M
Quality Metrics
Altman Z-Score3.33
Piotroski F-Score2 / 9
FCF Margin-238.9%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $139.7M
Diluted EPS-$0.69TTMFY2025: $-0.81
Dividend
No dividend
Capital Allocation
Capex Intensity8.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Precision Genetic Medicines | $139.7M | +120.0% | View detailsBLA submission for risto-cel expected as early as year-end 2026; pivotal cohort initiation for BEAM-302 planned for 2H 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.